Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 1 of 3 (33%) have an AI response strategy ready
Csl Behring Lengnau AG currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are spread across 3 distinct examiners and 3 distinct art units. This one-to-one ratio between actions, examiners, and art units indicates a diverse set of active cases within the pharmaceutical sector, with no concentration in any single administrative group.
KIM, YUNSOO is the busiest examiner for the company, holding 1 pending office action. With a busiest examiner pending count of 1 and a total of 3 pending actions, the workload is evenly distributed among the assigned examiners. This lack of concentration suggests that the company's current prosecution strategy involves multiple distinct technological paths or examiner interactions. For practitioners, this distribution means that the portfolio's overall success is not dependent on any single examiner's individual tendencies.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, YUNSOO | 1 | 66.0% | +34.0% |
| MULDER, SCOTT EVAN | 1 | 37.5% | +61.8% |
| ZINGARELLI, SANDRA | 1 | 6.7% | +46.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17623398 | A TRUNCATED VON WILLEBRAND FACTOR (VWF) FOR INCREASING THE IN VITRO STABILITY OF COAGULATION FACTOR VIII | ZINGARELLI, SANDRA | 23d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17775704 | POLYPEPTIDES FOR INDUCING TOLERANCE TO FACTOR VIII | MULDER, SCOTT EVAN | 113d overdue |
| 17623398 | A TRUNCATED VON WILLEBRAND FACTOR (VWF) FOR INCREASING THE IN VITRO STABILITY OF COAGULATION FACTOR VIII | ZINGARELLI, SANDRA | 23d overdue |
| 17782404 | STABLE COMPOSITIONS OF FC MULTIMERS | KIM, YUNSOO | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1656 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17782404 | STABLE COMPOSITIONS OF FC MULTIMERS | KIM, YUNSOO | 1641 | §103 | Non-Final OA | — | Pending | Jun 03, 2022 |
| 17775704 | POLYPEPTIDES FOR INDUCING TOLERANCE TO FACTOR VIII | MULDER, SCOTT EVAN | 1656 | §103 | Non-Final OA | 113d overdue | AI Ready | May 10, 2022 |
| 17623398 | A TRUNCATED VON WILLEBRAND FACTOR (VWF) FOR INCREASING THE IN VITRO STABILITY OF COAGULATION FACTOR VIII | ZINGARELLI, SANDRA | 1653 | §103§112 | Final Rejection | 23d overdue | Pending | Dec 28, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCsl Behring Lengnau AG has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Yunsoo Kim has the most, with 1 of Csl Behring Lengnau AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
